967 related articles for article (PubMed ID: 33573699)
1. Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial.
JamaliMoghadamSiahkali S; Zarezade B; Koolaji S; SeyedAlinaghi S; Zendehdel A; Tabarestani M; Sekhavati Moghadam E; Abbasian L; Dehghan Manshadi SA; Salehi M; Hasannezhad M; Ghaderkhani S; Meidani M; Salahshour F; Jafari F; Manafi N; Ghiasvand F
Eur J Med Res; 2021 Feb; 26(1):20. PubMed ID: 33573699
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
[TBL] [Abstract][Full Text] [Related]
4. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Hosseini FS; Malektojari A; Ghazizadeh S; Hassaniazad M; Davoodian P; Dadvand H; Nikpoor AR; Nikoofal-Sahlabadi S; Kahoori S; Sepandi M; Hassanipour S; Fathalipour M
Trials; 2021 Jan; 22(1):4. PubMed ID: 33397429
[TBL] [Abstract][Full Text] [Related]
6. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
Ader F; Peiffer-Smadja N; Poissy J; Bouscambert-Duchamp M; Belhadi D; Diallo A; Delmas C; Saillard J; Dechanet A; Mercier N; Dupont A; Alfaiate T; Lescure FX; Raffi F; Goehringer F; Kimmoun A; Jaureguiberry S; Reignier J; Nseir S; Danion F; Clere-Jehl R; Bouiller K; Navellou JC; Tolsma V; Cabié A; Dubost C; Courjon J; Leroy S; Mootien J; Gaci R; Mourvillier B; Faure E; Pourcher V; Gallien S; Launay O; Lacombe K; Lanoix JP; Makinson A; Martin-Blondel G; Bouadma L; Botelho-Nevers E; Gagneux-Brunon A; Epaulard O; Piroth L; Wallet F; Richard JC; Reuter J; Staub T; Lina B; Noret M; Andrejak C; Lê MP; Peytavin G; Hites M; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
Clin Microbiol Infect; 2021 Dec; 27(12):1826-1837. PubMed ID: 34048876
[TBL] [Abstract][Full Text] [Related]
7. Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
Kalantari S; Fard SR; Maleki D; Taher MT; Yassin Z; Alimohamadi Y; Minaeian S
J Med Virol; 2021 Dec; 93(12):6557-6565. PubMed ID: 34255369
[TBL] [Abstract][Full Text] [Related]
8. Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial.
Alavi Darazam I; Shokouhi S; Mardani M; Pourhoseingholi MA; Rabiei MM; Hatami F; Shabani M; Moradi O; Gharehbagh FJ; Irvani SSN; Amirdosara M; Hajiesmaeili M; Rezaei O; Khoshkar A; Lotfollahi L; Gachkar L; Dehbsneh HS; Khalili N; Soleymaninia A; Kusha AH; Shoushtari MT; Torabinavid P
Int Immunopharmacol; 2021 Oct; 99():107969. PubMed ID: 34273635
[TBL] [Abstract][Full Text] [Related]
9. Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir.
Rahmani H; Davoudi-Monfared E; Nourian A; Nabiee M; Sadeghi S; Khalili H; Abbasian L; Ghiasvand F; Seifi A; Hasannezhad M; Ghaderkhani S; Mohammadi M; Yekaninejad MS
Daru; 2020 Dec; 28(2):625-634. PubMed ID: 32857301
[TBL] [Abstract][Full Text] [Related]
10. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Davoudi-Monfared E; Rahmani H; Khalili H; Hajiabdolbaghi M; Salehi M; Abbasian L; Kazemzadeh H; Yekaninejad MS
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32661006
[TBL] [Abstract][Full Text] [Related]
11. Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults.
Ader F;
BMJ Open; 2020 Sep; 10(9):e041437. PubMed ID: 32958495
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.
Solaymani-Dodaran M; Ghanei M; Bagheri M; Qazvini A; Vahedi E; Hassan Saadat S; Amin Setarehdan S; Ansarifar A; Biganeh H; Mohazzab A; Khalili D; Hosein Ghazale A; Reza Heidari M; Taheri A; Khoramdad M; Mahdi Asadi M; Nazemieh M; Varshochi M; Abbasian S; Bakhtiari A; Mosaed R; Hosseini-Shokouh SJ; Shahrokhi M; Yassin Z; Ali Zohal M; Qaraati M; Rastgoo N; Sami R; Javad Eslami M; Asghari A; Namazi M; Ziaie S; Jafari-Moghaddam R; Kalantari S; Memarian M; Khodadadi J; Hossein Afshari M; Momen-Heravi M; Behzadseresht N; Reza Mobayen A; Mozafari A; Movasaghi F; Haddadzadeh Shoushtari M; Moazen J
Int Immunopharmacol; 2021 Jun; 95():107522. PubMed ID: 33735712
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial.
Ghanei M; Solaymani-Dodaran M; Qazvini A; Ghazale AH; Setarehdan SA; Saadat SH; Ghobadi H; Hoseininia S; Elahikhah M; Samadi AH; Imani Y; Vahedi E; Babamahmoodi F; Rostami FT; Ardebili MHA; Ansarifar A; Golmaei FF; Asadollah A
Respir Res; 2021 Sep; 22(1):245. PubMed ID: 34526033
[TBL] [Abstract][Full Text] [Related]
14. The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial.
Denholm JT; Davis J; Paterson D; Roberts J; Morpeth S; Snelling T; Zentner D; Rees M; O'Sullivan M; Price D; Bowen A; Tong SYC;
Trials; 2020 Jul; 21(1):646. PubMed ID: 32665040
[TBL] [Abstract][Full Text] [Related]
15. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
Kim JW; Kim EJ; Kwon HH; Jung CY; Kim KC; Choe JY; Hong HL
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S253-S263. PubMed ID: 32536150
[TBL] [Abstract][Full Text] [Related]
16. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.
Vernaz N; Agoritsas T; Calmy A; Gayet-Ageron A; Gold G; Perrier A; Picard F; Prendki V; Reny JL; Samer C; Stirnemann J; Vetter P; Zanella MC; Zekry D; Baggio S
Swiss Med Wkly; 2020 Dec; 150():w20446. PubMed ID: 33382449
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial.
Tabarsi P; Barati S; Jamaati H; Haseli S; Marjani M; Moniri A; Abtahian Z; Dastan A; Yousefian S; Eskandari R; Saffaei A; Monjazebi F; Vahedi A; Dastan F
Int Immunopharmacol; 2021 Jan; 90():107205. PubMed ID: 33214093
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial.
Liu P; Huang Z; Yin M; Liu C; Chen X; Pan P; Kuang Y
Trials; 2020 Dec; 21(1):999. PubMed ID: 33276811
[TBL] [Abstract][Full Text] [Related]
20. Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort.
Karolyi M; Pawelka E; Mader T; Omid S; Kelani H; Ely S; Jilma B; Baumgartner S; Laferl H; Ott C; Traugott M; Turner M; Seitz T; Wenisch C; Zoufaly A
Wien Klin Wochenschr; 2021 Apr; 133(7-8):284-291. PubMed ID: 32776298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]